Here are the most relevant search results for "GL CHEMTEC INTERNATIONAL LIMITED" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about GL CHEMTEC INTERNATIONAL LIMITED for you to read. Along with our medical data and news we also list GL CHEMTEC INTERNATIONAL LIMITED Clinical Trials, which are updated daily. BioPortfolio also has a large database of GL CHEMTEC INTERNATIONAL LIMITED Companies for you to search.
Only Vertically-Integrated Hemp Oil Company Expands to 48 States Functional Remedies, the only vertically-integrated manufacturer of whole-plant hemp oil products, announced a major expansion of its distribution networks in key U.S. markets. Functional Remedies signed five new agreements with natural retail broker networks to expand the distribu...
Rite Aid and GNC Announce Extension of Partnership Through 2022
Rite Aid Corporation (NYSE: RAD), one of the nation’s leading drugstore chains, and GNC (NYSE: GNC), a leading global specialty retailer of health and wellness products, announced today an agreement which extends their partnership through 2022. Rite Aid and GNC have had an exclusive partnership in the chain drug channel since December 1998. This press rel...
CRISPR Sleight of Hand Generates Immunologically Invisible Stem Cells
An international research team has used CRISPR-Cas9 gene editing to render induced pluripotent stem cells (iPSCs) invisible to the immune system, a bioengineering sleight of hand that initial in vivo tests suggest could open the door to generating stem cells for universal transplantation. The new approach, developed by scientists at the University of California, San […] The post CRISPR Sleig...
BioPortfolio.com - Valuation and Opportunity to Acquire BioPortfolio Limited
Dorchester, 19th February 2019: Following the circulation of our Private Memorandum Document - "BioPortfolio Ltd - Acquisition Opportunity" last month we are forwarding further details on pricing and our proposed stages to conclude the transfer of the business to a new owner. Valuation Peter Barfoot is anticipating between two to three times annual turnover. For the curr...
– Pure-Vu® System found to be simple, safe and effective in cleansing inadequately prepared colons during a colonoscopy achieving a 98% success rate in patients that had minimal bowel preparation – – Data supports potential of Pure-Vu® System to improve clinical outcomes while reducing costs and complications associated with conventional p...
A recent Mayo Clinic study published in Climacteric: The Journal of the International Menopause Society indicates that practicing mindfulness may be one solution for women suffering from menopausal symptoms, including vaginal dryness, as a way to reduce anxiety and stress, as symptoms can be related not only
Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its fourth quarter and full year 2018 financial and operating results on Tuesday, February 26, 2019. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and prov...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its fourth quarter and full year 2018 financial results will be re...
Visual problems often overlooked during initial treatment of a brain injury; Left untreated, can have serious consequences The College of Optometrists in Vision Development (COVD) and the Neuro Optometric Rehabilitation AssociationTM (NORA), today, issued a joint call-to-action to all healthcare professionals to consider the need for medical and...
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, February 27, 2019 at 5:00 p.m. EST to discuss its fourth quarter and full year 2018 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's we...
Outcomes Following Pelvic Exenteration for Rectal Cancer
Data from an international collaboration provides insight into the outcomes and prognosis of patients who have undergone pelvic exenteration for rectal cancer. Annals of Surgery
DGAP-News: ADL Bionatur Solutions / Key word(s): Alliance 19.02.2019 / 11:31 The issuer is solely responsible for the content of this announcement. Nutricion Center NC and ADL Bionatur Solutions sign a strategic alliance to tackle weight control by rebalancing the gut microbiome - First age-specific products for weight control by addressing the gastrointestinal microbiome - ADL Bionat...
Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call in conjunction with the announcement of its fourth quarter and full-year 2018 financial results and present at the 8th Annual Leerink Partners Health Care Conference. Details of both event...
Paul H. Sighinolfi Joins Ametros as Senior Managing Director
Paul H. Sighinolfi has joined the Ametros Senior Leadership team as Senior Managing Director. Bringing with him a wealth of knowledge and experience, he will provide thought leadership and lead regulatory and policy initiatives, while providing meaningful strategic direction and insight. This press release features multimedia. View the full release here: h...
RSP Systems to Exhibit Its Cutting-Edge Non-Invasive Glucose Monitor, GlucoBeam at ATTD 2019
RSP Systems, a Danish medical technology company focused on using state-of-the-art optical technology to non-invasively measure glucose, will showcase its advancements in product development and unveil – for the first time – its innovative device, GlucoBeam. ODENSE, Denmark, February 19, 2019 / B3C newswire / -- RSP Systems A/S, a Danish medical technology company focused on the develo...
Hardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
Hardman & Co Research 19-Feb-2019 / 07:15 GMT/BST Hardman & Co: Transformed and de-risked Yourgene Health (YGEN) is an international molecular diagnostics group that uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests (NIPT). Its flagship IONA test uses complex statistical analyses to determine the likelihood that a fetus is carrying a gene...
Interim report for Enzymatica AB (publ) ...
Brain imaging indicates potential success of drug therapy in depressive patients
Working with international partners, a MedUni Vienna research group has shown that imaging techniques carried out prior to treatment indicate the potential success of drug therapy in depressive patients.
Pea protein, Nanogels and Particle adhesion on surfaces
From 22-23 May 2019 LUM GmbH hosts the 9th International Conference Dispersion Analysis & Materials Testing in Berlin, Germany. Since 2014 the Young Scientist Award (YSA) recognizes outstanding scientific work by young researchers in the areas of particle and dispersion characterization and material...
Unexpected Genetic Vulnerability to Menthol Cigarette Use
Unexpected Genetic Vulnerability to Menthol Cigarette Use Reporter: Irina Robu, PhD According to a study published in PLOS genetics, a group of international researchers supported by U.S. Food and Drug Administration and the National Institute of Health have found a genetic variant of MRGPRX4 gene in people of African descent that increases a smoker’s preference […]
Quotient Limited to Host Investor Day and Ring Closing Bell at the NASDAQ on March 4, 2019
JERSEY, Channel Islands, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company will host an Investor Day on Monday, March 4, 2019 from 1:00pm – 3:00pm ET, in New York, NY. Following the Investor Day, the Company’s Chief Executive Officer, Franz Walt, will ring the Closing Bell of the NASDAQ Stock Exchange....
Glen Rock, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the treatment of sleep-related breathing disorders, is pleased to announce that it has entered into a non-binding memorandum of understanding (“MOU”) and exclusivity agreement with Impression Hea...
Alimera Sciences, Inc.: Alimera Sciences Reports Record Fourth Quarter and 2018 Results
Fourth Quarter 2018 Highlights Fourth quarter 2018 consolidated net revenue up 66% International segment revenue increased 138% over the prior year period Net Loss of $1.2 million vs. Net Loss of $...
10 Major Themes Driving The Future of Blockchain in Healthcare
Partners in Digital Health, communications company publishing the peer review journals Blockchain in Healthcare Today (BHTY) has announced their first annual BHTY Top 10 Blockchain Predictions for Healthcare 2019. With over 20,000 downloads, 18 citations, and readership in over 65 countries worldwide, Blockchain Healthcare Today (BHTY) is the preeminent open-access international peer-revi...
Inventiva Announces Results From Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis
Inventiva Announces Results From Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis Primary endpoint of the trial was not met, no statistically significant difference between the placebo and lanifibranor treated groups for the primary outcome Favorable safety profile of lanifibranor observed Decision to discontinue further developments in the treatment of ...